Jazz Pharmaceuticals Acquires AlizÃ© Pharma II
A subsidiary of Jazz Pharmaceuticals, a pharmaceutical company based in Dublin, Ireland,has acquired AlizÃ© Pharma II, part of AlizÃ© Pharma, a Lyon, France-headquartered pharmaceutical company for EUR 18 million ($20.4 million), oncluding an upfront payment of EUR 8 million ($9.1 million) and potential payments of up to EUR 10 million ($11.3 million) related to regulatory milestones. The transaction did not involve the transfer of any employees from the AlizÃ© Pharma Group to Jazz Pharmaceuticals. The deal closed in March 2016 and was announced in early May 2016.
AlizÃ© Pharma II was created in 2008. Prior to the closing of this transaction, its shareholders were TAB Consulting, Octalfa, CEMA and Sham Innovation SantÃ©. The company's lead assets are Asparec (pegcrisantaspase, a PEGylated recombinant L-asparaginase from Erwinia chrysanthemi, and related intellectual property. In February 2012, AlizÃ© Pharma II announced that it had licensed these assets to EUSA Pharma, which was subsequently acquired by Jazz Pharmaceuticals.
Source: AlizÃ© Pharma